Published: 21 December 2025
Wesfarmers Limited (ASX:WES) enters the final stretch of 2025 with a familiar investor appeal—dominant retail brands, a diversified portfolio, and steady cash generation—colliding with a very modern set of storylines: a group-wide rollout of ChatGPT Enterprise, fresh turbulence in parts of the Priceline pharmacy network, and an analyst community that largely thinks the stock is priced for perfection.
As of this Sunday (21 December 2025), the ASX is closed, so the key reference point is Friday’s close. Wesfarmers shares last finished at A$81.02 (19 December), with the stock up about 13% year-to-date by some market tallies.
Below is the full news-and-forecast picture investors are weighing right now—what’s happened, what analysts expect next, and what could move the Wesfarmers share price heading into 2026.
Wesfarmers share price today (21 Dec 2025): where WES stands
Because it’s the weekend, “today’s” Wesfarmers share price is effectively the most recent close:
- Last close (Fri 19 Dec 2025): A$81.02, up 0.35% on the day
- Recent trading range: data providers show recent sessions fluctuating roughly around the low A$80s (mid-December prints include A$79–A$81)
- 52-week range (as displayed by one widely used market data page):A$67.70 to A$95.18
- Market cap (same source): about A$92 billion
Those numbers matter because they frame the big investor debate: is Wesfarmers a high-quality compounder temporarily “on sale,” or a high-quality compounder that’s still expensive even after normal pullbacks? (We’ll come back to how analysts are answering that.)
What is Wesfarmers—and why WES is always in the spotlight
Wesfarmers is not a single retail chain. It’s one of Australia’s largest listed groups, spanning home improvement (Bunnings), discount department retail (Kmart Group), office supplies (Officeworks), health and beauty (Wesfarmers Health / Priceline-related assets), industrial distribution, and more—plus exposure to an integrated lithium joint venture in the portfolio mix.
That diversification helps explain why WES can look “defensive” in one cycle and “growthy” in another. When consumer spending is soft, value-oriented retail can hold up; when capital spending lifts, industrial and supply-chain-linked operations can improve; when the commodity cycle turns, lithium exposure can swing sentiment.
The biggest Wesfarmers stock news in December 2025
1) Priceline headline: 54 pharmacies placed into administration/receivership process
The most immediate, concrete headline for Wesfarmers investors late this week came via the Health division’s orbit: more than 50 Priceline-branded pharmacies were placed into administration after financial difficulties at Infinity Pharmacy Group (IPG), which operated the affected stores. Receivers have stated the 54 stores will continue trading while an assessment is conducted, and reports indicated other Priceline stores were not affected.
A key detail for investors is where the financial exposure may sit. In reporting around the event, Australian Pharmaceutical Industries (API)—owned by Wesfarmers—was described as having provided support and, as a creditor, taking steps viewed as “unavoidable” given IPG’s position. 9News+1
Another twist: medical equipment supplier Paragon Care publicly said it had been working with IPG and other parties (including Wesfarmers Health) on a restructure plan and was “surprised and disappointed” by the move to appoint receivers/administrators—signalling multi-creditor complexity that could take time to resolve. Company Announcements
Why the market cares:
Even if store operations continue normally in the short term, this episode raises investor questions about:
- wholesale credit exposure (API as supplier/creditor),
- the health retail operating environment (margin pressure, costs, regulation),
- and reputational/brand implications if closures or franchise disruptions expand.
Wesfarmers also provides context on what “Priceline scale” means inside the group: its Health division describes Priceline Pharmacy as a leading pharmacy brand with hundreds of community pharmacies, plus non-pharmacy Priceline stores, operating largely through franchise partnerships. Wesfarmers
2) Wesfarmers’ AI push: ChatGPT Enterprise roll-out via OpenAI partnership
On the opportunity side of the ledger, Wesfarmers has been turning up the volume on AI.
In late November, the company announced a partnership with OpenAI to make ChatGPT Enterprise available across the Wesfarmers Group, paired with customised training programs, positioning the move as part of a broader effort to lift productivity and improve customer experiences in-store and online.
This isn’t just a “cool tech” headline. The investment thesis angle is straightforward: if a retailer can meaningfully reduce friction in customer service, inventory decisions, merchandising, and internal workflows—without blowing up risk controls—AI can be an operating leverage story.
The timing also aligns with OpenAI’s broader Australia push. OpenAI has announced an “OpenAI for Australia” initiative including infrastructure planning with data centre operator NEXTDC, alongside workforce and ecosystem ambitions. OpenAI
And in local coverage, OpenAI’s Academy initiative has been presented as a practical skills pathway, with partner programs aiming to deliver AI literacy training at significant scale starting in 2026.
Why the market cares:
For a conglomerate like Wesfarmers, AI is less about one killer app and more about hundreds of small process wins—training, knowledge search, staff enablement, customer support, supply chain decisions. The upside is real, but investors will be watching for disciplined governance: hallucination risk, data handling, and decision accountability.
3) The capital return that changed the shareholder “math” in 2025
A major capital-management milestone is now in the rear-view mirror, but it still matters for how investors frame WES.
Wesfarmers executed a $1.50 per share capital management distribution comprising:
- $1.10 per share return of capital
- $0.40 per share fully franked special dividend
The company states the total distribution was about $1.703 billion, and it was paid on 4 December 2025, with an entitlement record date of 6 November 2025.
Wesfarmers also sets out how it funded the initiative, pointing to cash flows from asset sales (including disposal of its remaining Coles interest and divestments such as Coregas, among others).
Why the market cares:
Big capital returns can improve shareholder sentiment, but they also change the “valuation lens.” After a distribution, investors often ask: is the stock price now justified by the post-return earnings base and growth outlook?
4) Smaller but current disclosures: Tax Contribution Report and December ASX notices
In December, Wesfarmers also released its 2025 Tax Contribution Report as an ASX announcement (not typically a price-moving event, but relevant to governance and stakeholder reporting).
Other December notices included director interest changes and equity-plan related updates.
Wesfarmers stock forecast: what analysts are projecting (as of 21 Dec 2025)
Analyst consensus is not euphoric right now.
One consolidated market view (drawing on a group of analysts) shows:
- Mean consensus: Underperform
- Consensus label: Sell
- Number of analysts:13
- Average target price:A$80.82
- Last close used:A$81.02
In other words: the average target sits roughly in line with (or slightly below) where the stock last traded—implying limited upside on that specific consensus snapshot.
Why the targets diverge
Even with a “Sell/Underperform” headline, the market reality is that Wesfarmers inspires disagreement:
- Bulls see a premium-quality operator with category-leading brands and long-term compounding potential.
- Bears see a premium-quality operator that the market has already priced as though execution risk is close to zero.
You can see that tension echoed in broker commentary headlines around the post-capital-return period, including notes flagging valuation concerns and downward target revisions from some research houses earlier in the quarter.
Fundamentals recap: what the last full-year results said
The most recent full-year reporting cycle (FY2025, year ended 30 June 2025) showed a strong profit outcome, supported by retail performance and asset-sale-related factors.
In late August, reporting noted Wesfarmers posted a statutory NPAT of A$2.926 billion and highlighted contributions from retail segments plus gains linked to the Coregas sale.
That matters for December investors because it connects directly to two drivers still shaping sentiment:
- Capital discipline (including returning surplus capital), and
- Portfolio reshaping (asset sales and reinvestment focus).
The “2026 narrative”: what’s bullish and what’s risky for WES
The bullish case
- Operational excellence at scale: Wesfarmers’ portfolio approach lets it spread best practices and investment muscle across multiple brands and supply chains.
- AI as an efficiency engine: The OpenAI partnership and ChatGPT Enterprise deployment is a tangible mechanism for productivity improvements—if well governed and well adopted.
- Capital management credibility: The completed $1.50 distribution reinforces a shareholder-return framework that many long-term investors prize.
The bear case
- Valuation sensitivity: Consensus targets clustering around the current price suggest analysts see less margin for error than they’d like.
- Health division headline risk: The administration process affecting 54 Priceline-branded pharmacies is a reminder that parts of the health retail ecosystem can face structural pressure (costs, regulation, pharmacy economics).
- Macro and domestic cost pressures: In a wide-ranging CEO interview published this month, Wesfarmers’ chief executive warned about Australia facing an economic “tipping point,” pointing to domestic cost pressures and productivity challenges—exactly the kind of backdrop that can make retail earnings more demanding to defend. The Australian
Key dates and catalysts to watch next
Here are the next “hard calendar” items that could reset forecasts and move the Wesfarmers share price:
- 19 February 2026: Wesfarmers’ 2026 Half-year Results announcement & briefing
And here are the “soft catalysts” investors will likely track between now and then:
- Any trading or financial updates tied to the Priceline/IPG receivership process, including whether stores are sold, restructured, or consolidated (and what that implies for creditors and the broader franchise network).
- Signs that the ChatGPT Enterprise rollout is producing measurable benefits—faster workflows, better customer experience metrics, improved team capability—without creating risk blow-ups.
- Broader Australian market sentiment into early 2026, where “quality defensives” can either be bid up further (if uncertainty rises) or rotate out (if investors chase higher-beta growth).
Bottom line: Wesfarmers stock faces a classic “quality vs price” showdown
On the facts available as of 21 December 2025, Wesfarmers stock sits near A$81, coming off a year that included a large capital distribution, continued strategic reshaping, and a fresh December headline in the health retail ecosystem.
The market’s forward-looking argument is tighter: analysts, in aggregate, currently lean cautious with an average target around the latest trading level—suggesting the stock may need either (a) stronger-than-expected earnings delivery, (b) clearer AI-driven productivity outcomes, or (c) improved visibility around the Health division’s pharmacy exposure to justify meaningful upside from here.
